Regeneron Pharmaceuticals, Inc. | 374.05 / +0.10% |
Date/Time | 12/12 / 20:24 |
Chg. / Chg.(%) | 0.37 / +0.10% |
Bid | 373.43 / 2 |
Ask | 374.23 / 2 |
Open | 373.95 |
Previous Close | 373.68 |
High | 382.06 |
Low | 372.63 |
Volume [USD] | 10,132,402.61 |
Volume [Units] | 43,465 |
Price fixings | 238 |
ISIN | US75886F1075 |
Security | REGN |
Exchange | Cboe US |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
NASDAQ | 374.0100 | ![]() |
515,952 |
Cboe US | 374.05 | ![]() |
43,465 |
IEX | 374.04 | ![]() |
19,417 |
London Inter.. | 378.29 | ![]() |
779 |
TradeGate | 339.100 | ![]() |
40 |
Stuttgart | 336.150 | ![]() |
21 |
München | 337.50 | ![]() |
1 |
Hamburg | 333.40 | ![]() |
0 |
Frankfurt | 333.9000 | ![]() |
0 |
Düsseldorf | 339.65 | ![]() |
0 |
Berlin | 336.65 | ![]() |
0 |
Vienna Globa.. | 339.80 | ![]() |
0 |
gettex | 336.100 | ![]() |
|
Lang & Schwa.. | 339.00 | ![]() |
|
Mexico | 7,137.23 | ![]() |
539 |
SIX Swiss Ex.. | 304.89 |
News
- Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
12/10/2019 / 14:30 - GlobeNewswire - Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/09/2019 / 23:00 - GlobeNewswire - Ziopharm Oncology Presents Pre-Clinical Data Validating “Rapid Personalized Manufacture” (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting
12/08/2019 / 15:00 - GlobeNewswire - Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting
11/23/2019 / 15:00 - GlobeNewswire - Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis
11/20/2019 / 14:00 - GlobeNewswire